Quarterly Consolidated Statement Of Cash Flows

K Pharma,Inc. - Filing #7311570

Concept As at
2024-06-30
2024-01-01 to
2024-06-30
As at
2023-12-31
As at
2023-06-30
2023-01-01 to
2023-06-30
As at
2022-12-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-425,347,000 JPY
614,528,000 JPY
Impairment losses
2,677,000 JPY
36,497,000 JPY
Interest and dividend income
-14,000 JPY
-7,000 JPY
Decrease (increase) in inventories
4,028,000 JPY
1,250,000 JPY
Increase (decrease) in trade payables
97,000 JPY
99,005,000 JPY
Other, net
1,000 JPY
91,000 JPY
Subtotal
-521,712,000 JPY
850,421,000 JPY
Interest and dividends received
14,000 JPY
7,000 JPY
Income taxes paid
-40,747,000 JPY
-1,899,000 JPY
Net cash provided by (used in) operating activities
-562,445,000 JPY
848,528,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-9,306,000 JPY
-9,781,000 JPY
Net cash provided by (used in) investing activities
-9,306,000 JPY
-9,781,000 JPY
Cash flows from financing activities
Net cash provided by (used in) financing activities
JPY
-90,000 JPY
Net increase (decrease) in cash and cash equivalents
-571,752,000 JPY
838,656,000 JPY
Cash and cash equivalents
2,694,656,000 JPY
3,266,408,000 JPY
2,175,504,000 JPY
1,336,847,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.